Andrew Farlow's
teaching and communication

I teach on a mixture of Oxford graduate courses in global health and undergraduate courses in economics. I have lectured extensively all over the world including, in the years before the pandemic, fifty institutes across China.

Oxford International Health and Tropical Medicine course

For more than a decade I have taught a course on ‘Vaccine Deployment and Policies’ for the vaccinology module of the Oxford Masters in International Health and Tropical Medicine (I am told, to extremely good reviews). A one-page syllabus is here: Farlow Vaccine Economics and Deployment syllabus.

During the pandemic I did a couple of extra sessions. Since I only used them a couple of times and they were a lot of work to create, I share them fully here:

Farlow COVID-19 vaccines 2022-2023

Farlow Health Economics COVID-19 interventions November 2020

In previous years I have given an economic course on how to evaluate tools, especially for malaria (the content needs updating and will be posted soon).

In late 2022 I was asked to organise a Problem Based Learning Exercise for the students (a mix of IHTM vaccinology students and Jenner vaccine DPhil students).

The 2023 PBL, the first year of this new initiative, focussed on the “Future of Epidemic and Pandemic Vaccines to serve Global Public Health Needs” The PBL statement I set the students is here: 2023 Vaccinology PBL.

Five ask-the-expert sessions were organised. The students researched each expert then submitted questions to me in advance of the session, so that feedback could be given to tailor the questions. Discussion was run by the students, and questioning was deep and meaningful to their needs. The five experts kindly agreeing to join us were:

  • Professor Dame Sarah Gilbert: Professor of Vaccinology, University of Oxford. More here.
  • Professor Helen Rees: Founder and executive director of Wits RHI, University of the Witwatersrand, South Africa. More here.
  • Dr Joe Fitchett: Senior Adviser for Biotechnology at the Institut Pasteur de Dakar, Senegal. More here.
  • Professor Gary Kobinger: Director, Galveston National Laboratory at the University of Texas. More here.
  • Dr Stig Tollefsen:Technology Office Lead at CEPI (Coalition for Epidemic Preparedness Innovations). More here.

These sessions provided an opportunity to ask specific questions and sense check the developing recommendations for the PBL project. It was also intended to motivate the students and give them access to world-expert opinions and thinking.

One of the first batch of experts wrote after taking part:  “Oh my god my message is please please continue – this is the best learning format I have seen in my career. I guarantee you that they will remember what they learn there for the rest of their career because it is not just technical knowledge but knowledge that one learns along the way through more painful processes (and much more time). Combining this with the writing of papers is just phenomenal…. I will share the concept with some colleagues here…where I teach grad students.”

I supported the students and young researchers with a webinar too: Webinar Poster 2Feb23.

I gave a lecture to students in June 2023, a news item about which can be found here.

The 2024 PBL focussed on global flu pandemics. The PBL is here: 2024 Vaccinology PBL. A short news item is here.

Five ask-the-expert speakers were organised. Those kindly agreeing to join us were:

  • Professor Petro Terblanche, CEO of Afrigen Biologics & Vaccines, host of the new
    WHO mRNA tech transfer hub, talked about LMIC challenges and opportunities.
  • Spring Gombe, Market Access Africa (her Linkedin here) talked about access issues and strengthening Africa healthcare.
  • Christopher Chadwick (here, here, and here) previously at WHO now at CDC working on flu, gave a WHO/CDC related angle and discussed how to achieve equitable access.
  • Professor Bruno Versaevel: Professor at emylon business school, (his page here) a specialist in “industrial organization.. with a special interest in the economics of R&D in the biopharmaceutical industry context”, talked about tech transfer, investment, and pricing.
  • Dr Holly Sadler, consultant to WHO, talked about challenges of broadly protective (“universal”) flu vaccines, vaccine design, human and one health angles, epidemiology of influenza, implementation. 

The 2025 PBL focusses on malaria and mpox. The PBL is here: 2025 Oxford IHTM Vaccinology PBL

Details of the ask-the-expert speakers in 2025 will be shared shortly.

Ineos Oxford Institute for antimicrobial research graduate supervision

I supervise and/or transfer-examine students of Ineos Oxford Institute for antimicrobial research, especially those working across Africa, and in Pakistan and Malaysia.

In 2025 I launched a new DPhil in Food Systems and AMR. See here and here.

I have funded several IOI early career researchers to join international meetings and workshops.

The Hasso Plattner Institut, Potsdam, Germany has very kindly funded a DPhil student, to be jointly supervised by me and Professor Lothar Wieler (Speaker of the HPI Digital Health Cluster and Head of the research group “Digital Global Public Health”) in areas of mutual interest and that overlap with the work of a new partnership with CHAMPS. I am hoping we can connect more young researchers this way and create opportunities.

I have advised Oxford students and researchers on a wide range of global health research projects, including those taking the MSc Global Health Science, MBA projects, economic thesis, etc. Past projects have included:

  1. The R&D issues surrounding pediatric antiretrovirals for children with HIV;
  2. Vaccine strategies (in particular choice of vaccine) for global polio eradication;
  3. A comparative study of health system performance in several developing countries;
  4. The financial aspects of developing a telediagnostic kit and service for malaria and chikungunya infections in rural areas of Kenya;
  5. Needle-free vaccine technologies;
  6. Global health IP issues;
  7. Product Development Partnerships, governance and incentive issues;
  8. Pneumococcal vaccines;
  9. The economics of thermostable vaccines;
  10. Innovative’ global health financing;
  11. Dengue early-warning systems.

As best I can, I also give feedback to students from outside Oxford who inquire about their global health research projects.

Oxford Summer School: Global Health; Planetary Health; AI and the Future of Health

I have recently become involved in the Oxford Certificate Programmes Summer School at Worcester College, University of Oxford. My vision is for a summer school for young people (many of whom will have only just become exposed to global health issues and are exploring their options in life) and early career researchers in the area of global health.

The two-week Global Health and Planetary Health Syllabus is here: Farlow Global Health and Planetary Health syllabus

AI and the Future of Health. Syllabus is under edit and will be posted shortly.

‘AI and the Future of Health’ was piloted for the first time in 2024 with intent to extend in future years as part of a global effort to strengthen training of young people in AI for health. We are seeking funding that will allow us to fully fund half the attendees from LMICs to achieve this goal.

I also created a week on “Economic Crises and crashes” The syllabus is here: Farlow Crash syllabus

Participants graded my courses as excellent (5 out of 5) which will hopefully secure its future as a regular offering of the Worcester Programme. We also intend to link it so high-level policy summer schools and workshops. Watch this space!

Undergraduate economics teaching

I have taught Oxford undergraduates for over 30 years, variously macroeconomics and microeconomics from introductory level through to Finals (i.e. end of degree) level, the Industrial Organisation option paper for Finals, the Money and Banking paper for Finals, and some finance options at the Finals and MSc/MPhil level.

Currently I teach small groups for the Money and Banking Finals paper. I also organise a financial crash seminar every spring at which, with my guidance and support (copious visual content shared), students present and discuss.

Descriptions of all the Oxford undergraduate PPE (Politics, Philosophy and Economics) option papers are here. The description for the Money and Banking option is: The role of money in general equilibrium models. Aggregate models of price and output fluctuations. The role of banks and financial intermediaries. Models of monetary policy. Inflation targeting and other policy regimes. Money and public finance. The transmission of monetary policy to asset prices and exchange rates.

I am told that I am a deeply knowledgeable (I wrote a book about the crash after all!) and inspiring tutor for the Money ad Banking paper. Several students every year go on to further programmes of study in economics.

Currently I teach a few macroeconomics tutorials for the undergraduate Introductory Economics paper. The syllabus is described here.The macroeconomics component is described as covering: national income accounting; the determination of national income and employment; monetary institutions and the money supply; inflation; balance of payments and exchange rates; the determinants of long-run economic growth.

Some useful links for students are this and this.

Selected Presentations, Guest Lectures, and Meetings

Only up to 2018. This will be brought up to date in early 2025 in an effort to make a more permanent record.

June 2018: Oxford Global Leadership & Financial Innovation Programme (Chinese business delegates)Lecture 1: ‘Reflections on the Global Financial Crash: Lessons for China’, Lecture 2: ‘Financial instability in China: how to reduce risks, based on UK experience’.

November 2017: Rio de Janeiro, Brazil. 4rd International Symposium on Challenges and New Technologies in Drug Discovery and Pharmaceutical Production (IV CNTP), opening session speech. Symposium is organized by FARMANGUINHOS, part of the Oswaldo Cruz Foundation (FIOCRUZ)/ Brazilian Ministry of Health.

March-April 2017: China lecture tour: Peking University, Beijing Normal University, University of International Business & Economics, Minzu University of China, CUPL Changping, Tsinghua University, Renmin University of China, Shandong University; University of Electronic Science & Technology, Chengdu, Sichuan; Sichuan University; Wuhan University, Huazhong University of Sciecne & Technology, Hunan University, Zhongnan Univeristy, Xiamen University, Tongji University, East China Normal University, Nanjing University of Aeronautics and Astronautics, Nanjing Univeristy, Shanghai Jiaotong University, Tianjin University, Northwest University.

November 2016: Institut Pasteur, Paris. Final stakeholder meeting of the IDAMS and DENFREE Consortia in collaboration with WHO-TDR.

September 2015: Department of Medical Research, Yangon, Myanmar, Lecture ‘The Changing Global Impact of Dengue’.

September 2015: Thailand lecture and meetings Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok,Thailand.

June 2015: ‘Beyond Efficacy: The full public health of impact of vaccines in addition to efficacy measures in trials’ Fondation Merieux, Veyrier-du-Lac, France (link to published article).

January 2015: “Vaccination ecosystem health check: achieving impact today and sustainability for tomorrow”, Fondation Merieux, Veyrier-du-Lac, France.

February 2014: Mulago Hospital, Makerere University, Kampala, Uganda Workshop: Translating Global health technologies, DFG Priority Program Adaptation and Creativity in Africa.

June 2014: University Hospital Freiburg, Germany, Health Economics Seminar Series ‘Disease mapping and vaccine cost effectiveness: Opportunities and challenges’.

June 2014: Freiburg, Germany, Third expert meeting on effective, affordable and evidence based dengue early warning and response.

November 2013: London, Goldman Sachs SUSTAIN lunch event on ESG (Environmental, Social and Governance) themes. Talk on ‘Trends and innovations in global healthcare’.

October 2013: Oxford Tropical Network Meeting, Kilifi, Kenya. Talk  ‘The health and economic burden of dengue: Lessons for Africa, lessons from Africa’ and workshops.

September 2013: University of Nairobi, Kenya, Department of Economics ‘The Financial Crash: Causes, Responses, Consequences’.

September 2013: Copenhagen, Denmark, 8th European Congress on Tropical Medicine and International Health, (ECTMIH-2013).

July 2013: Freiburg, Germany, TDR-WHO expert meeting. Effective, affordable and evidence based dengue early warning and response systems: toward a validated contingency plan. University of Freiberg, Germany.

June 2013: National Institutes of Health, Washington DC, USA, Talk and discussion: “Dengue disease mapping and the economics of vaccines: Opportunities and challenges”

June 2013: Seattle, USA, Global Health metrics and Evaluation, conference.

February 2013: Accra, Ghana, meeting on dengue in Africa. I am also meeting colleagues in Ghana working on efforts to scale up renal transplant surgery in Africa.

July 2012:: Max-Planck-Institut für ethnologische Forschung, Halle, Germany, three-day workshop, ‘Relocating Science and Technology. Global Knowledge, Traveling Technologies and Postcolonialism. Perspectives on Science and Technology Studies in the Global South’, participant.

July 2012: Büro für Technikfolgeabschätzung beim Deutsschen Budestag (TAB), Berlin. Meeting with TAB regarding a project of German and other academics (on which I am an external advisor) to advise the German Bundestag (parliament) on ‘innovative and alternative concepts for drug development to improve health in African countries’

June 2012: TDR­ WHO expert meeting in cooperation with the University of Freiburg, Germany on ‘Effective, affordable and evidence based dengue early warning and response systems: Country case studies for sharing experiences’. Chair of economics session.

November 2011 onwards: Lecture for the Human and Veterinary Vaccinology of the Oxford Vaccinology Programme of the Department of Continuing Education.

November 2011: Stockholm, European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE), 6-8 November. Invited plenary speech: Enhancing health and health equity through vaccination programmes, session on ‘Economics and Societal Value of Vaccines’; I returned to the theme of the need for a higher-efficacy malaria vaccine goal and discussed progress on dengue vaccines. Conference sponsored by European Centre for Disease Control and Prevention (ECDC) and jointly organized by ECDC, EPIET (European Programme for Intervention Epidemiology), EAN (EPIET Alumni Network), TEPHINET EUROPE (Training Programs in Epidemiology and Public Health Interventions Network).   (some slides had copyright images removed before going online).

October 2011: Freiberg, Germany, IDAMS meeting.

June 2011: Wissenschaftscolleg zu Berlin, Colloquium (10 minute introduction, 50 minute presentation, one hour of questions) ‘The Financial Crash: Causes, Responses, Consequences’.

October 2011: Max-Planck-Institut für ethnologische Forschung, Halle, Germany, conference: ‘A World of Indicators: Knowledge Technologies of Regulation, Domination, Experimentation and Critique in an Interconnected World’. Presentation ‘Science, Innovation and Global Health Policy: The Evolving Role of Indicators’.

May 2011: 5-day meeting at Wissenschaftscolleg zu Berlin, ‘Caring for African Health Care: Reading Clinical Case Studies for Systemic Insights’. Meeting report  Caring for African Health Care: Reading Clinical Case Studies for Systemic Insights (pp308-317) by Steven Feierman and Julie Livingston.

October 2010-July 2011: Wissenschaftscolleg zu Berlin Focus groups: Limits to Disease Control – Failures in Disease (convened by Janis Antonovics of the Univeristy of Virgina) and Professional Dilemmas of Medical Practice in Africa (convened by Steven Feierman of the University of Pennsylvania and Julie Livingston of Rutgers University). The first focus group was a tremendous help in developing my thinking on which vaccines are more and less likely to suffer long-term declines in population-level efficacy on account of evolution, and how packages of interventions might better work given the workings of evolution. The second group encouraged me even more to develop policy that better serves the needs of those delivering medical care in resource-poor settings, and introduced me to some astonishing people who somehow mix academic thinking with medical practice and daily life in very resource-poor settings.

June 2010, Oriel College Oxford: Stop TB Partnership Working Group on New Vaccines: Task Force on Economics and Product Profiles, Presentation: Financing for TB Vaccines in a Financially-Constrained World.

May-June 2010 (31 May-3 June): Panama City, Panama, TDR (UNICEF/UNDP/World Bank/WHO) Disease Reference Group (DRG) on Dengue and other Emerging Viral Diseases of Public Health Importance. Stream 4: health policy research contributing to adequate public health response. Presentation: Factors Leading to Success or Failure of National Programmes and Global Funding in Dengue.

2007-2010: My approach to global health issues is highly collaborative. One objective has been to share knowledge and learning across different groups working on similar themes; good practice can therefore be picked up, shared and encouraged, and less good approaches can be avoided and replaced. Just recently, this has been extremely valuable in my thinking about TB and malaria vaccines, drugs and diagnostics in particular. The research group held in-depth meetings with the Malaria Vaccine Initiative (MVI); International AIDS Vaccine Initiative (IAVI); Aeras Global TB Vaccine Foundation; Foundation for Innovative New Diagnostics (FIND); International Partnership for Microbicides (IPM); TB Alliance; PATH (Human papillomavirus, meningitis, and Japanese encephalitis vaccine teams); Drugs for Neglected Diseases Initiative (DNDi); Novartis Institute for Tropical Diseases; Sanofi Pasteur; GlaxoSmithKline; InViragen; Hawaii Biotech; Merck Vaccines; Pfizer; WHO (Immunization Vaccines and Biologicals, and Initiative for Vaccine Research); GAVI Alliance; UNICEF; Oxford Insect Technologies (OXITEC); Swiss Tropical and Public Health Institute; Lille University; Imperial College London; Spatial Ecology and Epidemiology Group, Zoology Department, Oxford; Atmospheric, Oceanic and Planetary Physics, Oxford; the Institute for Emergent Infections of Humans, Oxford Martin School; and other Oxford infectious disease mapping researchers.

December 2010: UK Department of Health, International Division, Stakeholder meeting ahead of WHO Executive Board meeting in January 2010.

2008-2009: Encouraged by senior colleagues in the Bill and Melinda Gates Foundation, NIH, WHO,  industry, and academia (though not the business school where I was based), I encouraged the Bill and Melinda Gates Foundation to finally deal with PDVI, a failing PDP based inside the IVI in Korea, that had, in the words of leading Foundation figures, wasted large chunks of the money the Foundation had given it, mismanaged and bullied many grantees, slowed the advance of a portfolio of potential dengue vaccines, held back vital economic/impact work for at least five years, and failed to sufficiently advance an access agenda for dengue vaccines. For the first time, the Foundation held a competition to replace a PDP, removed managers, and set up a new collaboration, the DVI (that included parts of PDVI).

October 2009: Fondation Merieux, Veyrier-du-Lac, France. Second meeting of the Task Force on Economics and Product Profiles for new TB vaccines (WHO, Aeras Global TB Vaccine Foundation, and Bill and Melinda Gates Foundation).

September 2009: Vice Chancellor’s Global Health Research Forum, University of Oxford: Presentation: ‘“Where’s all the money gone?” Financial crisis and global health spending: Priority setting past, present and future’.

March 2009: Joint Committee on Vaccination and Immunisation (JCVI), varicella zoster subgroup meeting, Department of Health, London.

February 2009: International Consulting Economists’ Association, The Institute of Commonwealth Studies, London. Presentation: ‘The Global Financial Crisis: Causes and Cures’.

February 2009: G-FINDER (Global Funding of Innovation for Neglected Diseases), George Institute for international Health (project financed by Bill and Melinda Gates Foundation) report launch meeting, Royal College of Physicians, London. Short talk and panel member.

December 2008: London School of Hygiene and Tropical Medicine. First meeting of the Task Force on Economics and Product Profiles for new TB vaccines, presentation (WHO, Aeras Global TB Vaccine Foundation, and Bill and Melinda Gates Foundation).

November 2008: Health Impact Fund meeting, Lincoln College, Oxford. Response presentation and panel discussion.

November 2008: Zoology Dept, University of Oxford, ‘Science and Public Health Policy’ presentation and discussion.

October 2008: Pfizer Inc Headquarters, New York, ‘Global Health Access: The Challenges of Finance and Sustainability’.

November 2007: Organized a follow-up two-day meeting in Oxford pulling together two-dozen dengue modellers, in particular several groups in Oxford, economists, and researchers working on dengue burden of disease.

September 2007: ‘Oxford Conference on Innovation and Technology Transfer for Global Health’, inaugural conference ‘Bridging the Gap in Global Health Innovation — From Needs to Access’. Conference co-organiser, and speaker: ‘The intersection of economics and access’.  Conference financially supported by Bill and Melinda Gates Foundation.

July 2007: Managua, Nicaragua. Americas Dengue Prevention Board inaugural meeting. Presentation and discussion: ‘Dengue vaccine: An assessment of market, coordination, and risk factors’.

July 2007: Aeras Global Vaccine Foundation, and Bill and Melinda Gates Foundation. Presentation in Washington: ‘An Independent Assessment of Tuberculosis Vaccines: The Case for Investment’. 2.5 hour slot in an all-day Aeras and BMGF meeting to discuss the case for investment during Aeras grant renewal process.

July 2007: 2020 Health. All-party (UK Parliament MPs and Lords) meeting, London. Discussant and (after the event) reviewer of report: ‘Modern Vaccines, Modern World’.

June 2007: I  organized and lead a day-long workshop pulling together three teams of dengue transmission modelers and several groups working on dengue economics (about 25 individuals from Switzerland, Lille, US, UK (London and Oxford)), to explore methological strengths and weaknesses, set up guidelines and standards for work on the economics of dengue vaccines, and to improve the consistency of dengue economics evidence to be used to guide vaccine introduction. The work was subsequently taken over by PDVI and then eventually DVI.

May 2007: MacArthur Foundation workshop on maternal mortality, University of Oxford. Social Science convenor. Presentation: ‘Magnesium Sulfate for the Management of Pre-Eclampsia and Eclampsia: Some Economic and Cost Reflections’.

May 2007: WHO Geneva missions (China, South Korea, Germany, Brazil). Discussions.

May 2007: International Policy Network, Intercontinental Hotel, Geneva, Switzerland. Presentation based on paper being launched, and debate: ‘A Global Medical Research and Development Treaty: An answer to global health needs?’

April 2007: Bill and Melinda Gates Foundation Workshop on Incentives for R&D, New York. A meeting to review recent work by the Office of Health Economics for BMGF on R&D incentives.  Asked to provide a peer review for the meeting.

April 2007: Woodrow Wilson School, Princeton, New Jersey. Public Lecture: ‘The State of Global Health Funding Initiatives’.

April 2007: PDVI Board of Counsellors meeting, Honolulu, Hawaii: presentation.

December 2006: Ho Chi Minh City, Vietnam. Asia Dengue Prevention Board inaugural meeting: presentation.

November 2006: Tanaka Business School, Imperial College, London, ‘Brainstorming meeting on universal access to HIV medicines’ (Imperial College London, Department for International Development [DfID], International HIV/AIDS Alliance, and Stop AIDS Campaign). Participant.

October 2006: Wellcome Trust, Vaccinology Frontiers Meeting, Hampshire, United Kingdom: ‘Bringing industry and academia together for the next generation of vaccines’. Presentation: ‘What are the economic drivers affecting vaccine R&D?’

September 2006-December 2008: Senior Research Fellow, Saïd Business School, Oxford. During this period I pulled together a research group of about ten people (seven full-ime and three part-time), was awarded $1.4 million in grant money, and led a  $50 million bid for work on global health (which in the end nobody was granted). From 2009 my institutional focus shifted back to working with those engaging in Oxford’s long-established and flourishing global health programs.

June 2006: Brussels. ‘Connecting the Chain:  A concerted “end to end” approach to the development of drugs and vaccines against poverty-related diseases’. High-level, invitational stakeholder forum (Netherlands Ministry of Foreign Affairs, European and Developing Countries Clinical Trials Partnership [EDCTP] and Netherlands-African Partnership for Capacity Development and Clinical Trials [NACCAP]). Invited participant.

2006: I helped to build a small (three-person) research group working on how to use modern marketing techniques to reach the ‘undelivered’ with vaccines, and to push vaccine coverage above 90% (I argued it would help PDVI lead the field on an issue that was neglected but becoming increasingly important). This was several years ahead of its times. Four years later the Bill and Melinda Gates Foundation announced a goal of scaling up the delivery of life-savings vaccines in developing countries to 90% coverage, and six years later the World Health Assembly of the WHO endorsed a plan to increase coverage amongst other moves. The Oxford team dispersed and moved on.

May 2006: Advised TB Alliance on TB Drug Development Portfolio Figures. Analysis of Monte Carlo simulations of TB drug portfolio.

April 2006: WIPO, the World Intellectual Property Organization, Geneva, Switzerland. Meeting: ‘Intellectual Property Management Strategies to Accelerate the Development and Access of Vaccines and Diagnostics: Case Studies on Pandemic Influenza, Malaria and SARS’. Invited participant/presenter. Paper produced from meeting here.

April 2006: Dengue Viral Entry.  Three-day scientific workshop in Oxford on dengue virus (virus-cell interactions, recognition and responses, ligands and APC receptors, cell interactions, lessons from other viruses and prospects for Flaviviruses). Participant.

September 2005: Malaria Vaccine Technology Roadmap, Oxford: Participant.

June 2005: Médecins Sans Frontières  (MSF) Campaign for Access to Essential Medicines, International Conference on Ensuring Innovation for Neglected Diseases, London, United Kingdom. Presentation: ‘The Cost of R&D: How Much Money is Needed to Address the Current Need?’

June 2005: The London Business School. Guest Lecture: ‘Housing, Consumption, and the Economy: Why do House Prices Become Misaligned, and What are the Consequences?’

June 2005: Geneva, Switzerland, WHO Commission on Intellectual Property Rights, Innovation and Public Health, stakeholder meeting. Participant.

April 2005: Biodesign Institute, Arizona State University, Pheonix, Arizona. Guest Lecture

January 2005: John D Wood & Co. London. Invited Paper and Guest Lecture: ‘UK House Prices, Consumption and GDP in a Global Context’.

February 2004: University Sains Malaysia, Penang, Malaysia, Neglected Diseases Group (NDG) Meeting. Presentation/discussant.

January 2004: Salzburg, Austria, Dutch Government and WHO. Presentation at Stakeholder meeting for 7th European Framework for projects in health (2007-2010).

December 2003: The Earth Institute at Columbia University, New York, The Program on Science, Technology, and Global Development. Conference ‘Access to Medicines and the Financing of Innovations in Health Care.’ Invited Presentation: ‘Costs of Monopoly Pricing Under Patent Protection’.

September 2003: The Rockefeller Foundation and Consumer Project on Technology. Bellagio, Italy, Conference: ‘New Framework for Supporting Health Research and Development.’ Invited Participant and Presentation: ‘Alternative Finance Ideas for Health R&D’.

July 2003: The Rockefeller Foundation, New York. Meeting on ‘Access to medicines and intellectual property’, covering a Review of TRIPS-Plus Provisions, TRIPS and Regional Markets, and Regional Pooled Procurement.

July 2003: The Ford Foundation, New York. Meeting on ‘International Trade and Intellectual Property Rules: Challenges to Safeguarding Public Health.’ Organised by The Ford Foundation, The Rockefeller Foundation, United Nations Development Program, and the Carnegie Council on Ethics and International Affairs.

July 2003: Oriel College, Oxford, Senior Library. During the celebrations to launch the Mandela Rhodes Foundation, organised a public lecture on ‘Democracy in South Africa’ for Patricia de Lille, leader of the Independent Democrats, a South African political party, who along with Nelson Mandela and others had helped to write the new Constitution of South Africa. The lecture, and discussion, was attended by about 100 Rhodes Scholars of all ages, including two US Senators. Organised meetings with a range of UK government Ministers and officials and with UK groups working on HIV.

May 2003: Credit Suisse First Boston, London, England. Invited presentation and paper: ‘UK House Prices: A Critical Assessment’.

Most of the above work with students and young researchers (especially non-summer school teaching) was done for very little payment or pro bono. If you think it worth sustaining and wish to financially support it, please get in contact.